Table 2.
MACEs by therapeutic drug class
| Number of MACEs | Incidence rate per 1000 PY (95% CI) | PY | Time before MACE median (IQR), months | Age at the event, mean (s.d.), years | Sex ratio (men:women) | |
|---|---|---|---|---|---|---|
| Total bDMARDs (n = 9510) | 43 (0.5) | 3.2 (2.2, 4.1) | 13 501.6 | 12 (5–22) | 60.8 (10.3) | 29:14 |
| Acute myocardial infarction | 28 (0.3) | 2.1 (1.3, 2.8) | 14 (5–22) | 60.8 (7.7) | 19:9 | |
| Cerebral infarction | 15 (0.2) | 1.1 (0.5, 1.7) | 9 (5–22) | 59.6 (14.3) | 10:5 | |
| TNF inhibitors (n = 7289) | 30 (0.4) | 2.8 (1.8, 3.9) | 10 519.3 | 12 (5–26) | 59.6 (11.4) | 21:9 |
| Acute myocardial infarction | 19 (0.3) | 1.8 (1.0, 2.6) | 15 (4–26) | 60.8 (7.4) | 15:4 | |
| Cerebral infarction | 11 (0.1) | 1.0 (0.4, 1.7) | 9 (5–34) | 58.3 (16.3) | 6:5 | |
| IL-12/23 inhibitor (n = 1058) | 5 (0.5) | 3.1 (0.4, 5.8) | 1627.5 | 10 (5–13) | 65.0 (7.6) | 2:3 |
| Acute myocardial infarction | 5 (0.5) | 3.1 (0.4, 5.8) | 10 (5–13) | 65.0 (7.6) | 2:3 | |
| Cerebral infarction | 0 (0.0) | 0.0 (0.0, 0.0) | – | – | – | |
| IL-17 inhibitors (n = 1163) | 8 (0.7) | 5.9 (1.8, 9.9) | 1354.9 | 14 (5–18) | 61.6 (7.8) | 6:2 |
| Acute myocardial infarction | 4 (0.3) | 2.9 (0.1, 5.8) | 13 (5–17) | 60.0 (9.3) | 2:2 | |
| Cerebral infarction | 4 (0.3) | 2.9 (0.1, 5.8) | 15 (6–20) | 63.2 (7.0) | 4:0 | |
| Apremilast (n = 1885) | 8 (0.4) | 5.2 (1.6, 8.9) | 1523.9 | 3 (2–14) | 66.6 (10.4) | 7:1 |
| Acute myocardial infarction | 5 (0.3) | 3.3 (0.4, 6.1) | 6 (2–22) | 68.0 (13.4) | 5:0 | |
| Cerebral infarction | 3 (0.1) | 1.9 (0.2, 4.2) | 2 (2–3) | 64.3 (7.6) | 2:1 |
Data are n (%) unless indicated. bDMARD: biological DMARD; PY: person-years; IQR: interquartile range; MACE: major adverse cardiovascular event.